The ICER’s novel and inclusive work on the value of drugs, using its own value framework and assessing the affordability, and even going so far as setting the value-based price benchmark of new drugs, has given payers powerful negotiating tools. The impact on pricing is being felt while drug affordability and access in the US’s overheated drug sector is touching a wider stakeholder community. But not everyone is convinced. Pharma questions the emphasis on drug costs as the main determinant of value in the health care system, use of list prices (which can differ from actual prices paid in the US system), and use of Quality Adjusted Life Year (QALY) as a measure of cost-effectiveness.
The fact is the ICER is well supported and here to stay. As all new drugs in the US will be subject to ICER scrutiny, companies would be wise to fully engage in order to respond to ICER’s negative results on their drugs, and benefit from positive ICER findings. That is why in Review of Influence: The Institute for Clinical and Economic Review (ICER) we interviewed leading experts in market access and Health Technology Assessment to help you understand where — and how — ICER will impact pharma and the steps industry can take to engage with ICER, and benefit from or challenge findings.